Previous Close | 0.1600 |
Open | 0.1650 |
Bid | 0.1950 x N/A |
Ask | 0.2000 x N/A |
Day's Range | 0.1650 - 0.2100 |
52 Week Range | 0.1350 - 0.3700 |
Volume | 15,503,328 |
Avg. Volume | 1,574,138 |
Market Cap | 69.901M |
Beta (5Y Monthly) | 1.93 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1030 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
OTTAWA, ON / ACCESSWIRE / March 8, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX: TBP)(OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development wishes to make the following correction to its news release dated February 25th, 2021.
OTTAWA, ON / ACCESSWIRE / March 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announces that CEO Dr.
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/OTTAWA, ON, March 2, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development, is pleased to announce it has closed its previously announced bought-deal public offering of units (the "Units") of the Company.